Annexin Pharmaceuticals AB (FRA:Q910) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:Q910 Annexin Pharmaceuticals AB FRA:Q910
20 GF Score
Price €1.14
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB FFO per Share?

FFO per Share only applies to REITs.

FRA:Q910
20GF Score
Annexin Pharmaceuticals AB FRA:Q910
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Business Description

Other Exchanges ANNX:Sweden
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
20GF Score

Get the complete analysis for FRA:Q910

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.14
Price